Speakers from last year's Conference
Prof. Donald E. Ingber
Organs on Chips - Alternative Testing and Future Drug Design
Forget cell cultures in petri dishes, because Prof. Ingber will introduce “organs-on-chips” to you. Chips that respond to drugs like human organs do – and have the potential to replace animal testing for safety and efficacy early in the drug-development process. The vision is to create personalized chips from harvested patient cells and to test how drugs will act in the specific case. He is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University. Dr. Ingber has made major contributions to cell biology, mechanobiology, bioengineering, tissue engineering, nanobiotechnology, angiogenesis, cancer, medical device development, and translational medicine. He has authored more than 400 publications and 125 patents, founded 4 startups, presented more than 450 presentations world-wide, and received numerous honors in a broad range of disciplines, including membership in the National Academy of Medicine, National Academy of Inventors, and the American Institute for Medical and Biological Engineering.
Prof. Ramanan Laxminarayan
State of the World’s Antibiotics – Past, Present and Future
Professor Ramanan Laxminarayan is an economist and epidemiologist by training. His research work deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource.
He has served on a number of advisory committees at the World Health Organization, Centres for Disease Control and Prevention, and the US National Academies of Science/ Institute of Medicine.
In 2014, Laxminarayan served on US President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group. He is currently a voting member of the US Presidential Advisory Council on Combating Antimicrobial Resistance. We are proud to welcome Prof. Laxminarayan opening the 27th European Students’ Conference with a general introduction talk about the state of the world’s antibiotics from his epidemiological point of view.
Watch Prof. Laxminarayan TedTalk below:
Prof. Dr. Lothar H. Wieler
Transmission pathways of resistant bacteria and resistance genes between humans and animals
Prof. Dr. Lothar H. Wieler is the president of the Robert Koch Institute, the central institution responsible for disease control and prevention in Germany. He is also a Professor at the Centre for Infection Medicine, Institute of Microbiology and Epizootics of the Freie Universität (FU) in Berlin. Prof. Wieler has received the Young Researchers award from the German Veterinary Association and the Main Award of the German Association for Hygiene and Microbiology.
His research focuses around infections caused by zoonotic agents as well as drug-resistant and multi-drug resistant bacterial pathogens. Molecular pathogenesis and risk assessment based on molecular functional infection epidemiology – utilizing latest molecular technologies - of bacterial pathogens is a discipline that has been moved ahead by him.
After the general introduction about the use and development of antimicrobial resistance in the veterinary medicine by Prof. Schwarz, Prof. Wieler will put his focus on transmission of these bacteria between the animals and humans. By doing so he will emphasize the importance of an One-Health-Approach to solve the problem of antimicrobial resistance.
Prof. Steffen Mitzner
Blood Circulation and Bioreactors: Sepsis therapy through immune cells
He is the Director of the Nephrology Department at the Universitätsmedizin Rostock and Head of Extracorporeal Immunomodulation Unit at the Fraunhofer Insitut. He was involved in the development of liver supporting system MARS and extracorporeal immune support system (EISS) and founded 3 companies in the field of Intensive Care Management. He is Steering Committee Member for the European MARS RELIEF study project and Overseas Adviser to the Albumin Dialysis Japan Center (ADJC).
The scientific focus of Prof. Mitzner’s work is on the development and testing of innovative therapies, on the basis of classic extracorporeal technology platforms, such as dialysis and plasma separation. Special emphasis is placed on the development of extracorporeal blood treatment methods for sepsis therapy.
Dominique L. Monnet
Antimicrobial Resistance: Current Risks and Future Threats for Europe
Head, Antimicrobial Resistance & Healthcare-Associated Infections (ARHAI) Programme European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Dominique L. Monnet joined ECDC in October 2007 to lead ECDC’s Disease Programme on Antimicrobial Resistance and Healthcare-Associated Infections. He is also representing ECDC in the EU-US Transatlantic Task Force on Antimicrobial Resistance (TATFAR).
Before joining ECDC, he worked in French hospitals, at the US Centers for Disease Control and Prevention (1993-1995) and at the Danish Statens Serum Institut (1997-2007) where he was coordinating surveillance of antimicrobial resistance and antimicrobial consumption in humans in Denmark.
His research interests include surveillance of antimicrobial resistance and antimicrobial consumption, the relationship between consumption of antimicrobials and resistance, and the factors that affect antimicrobial usage, both in hospitals and in primary care.
Dr. Kim Faure
The Challenges of Poor Countries while setting up AMR Action Plans
Dr. Kim Faure is an independent consultant to the healthcare industry with a specific focus on quality assurance systems, public policy and regulatory reforms and strategic initiatives.
She has conducted extensive regulatory, policy advisory and technical work for the National Department of Health (NDOH) to help develop quality standards and establish the Office for Health Standards Compliance. Dr Faure is currently also the South African Co-ordinator for the Center for Disease Dynamics, Economics and Policy (CDDEP), which is supporting the NDOH to develop a national strategy and policies to combat antimicrobial resistance and preserve our future antibiotics.
Dr Faure has more than 13 years experience and knowledge of health services, quality assurance, public health policy and regulatory frameworks. Having worked in both the public and private healthcare sectors in South Africa, she is one of the early pioneers of clinical governance and quality assurance systems in the country. She was medical director for Netcare UK and later helped implement clinical quality assurance for all clinical divisions within the Netcare group. She was also part of the Best Care…Always mentoring team in Gauteng, supporting the implementation of interventions to combat Hospital Associated Infections in the public sector.
Dr Faure counts the development of norms and standards for concurrent functions in health and the Front Line Service Delivery monitoring tools at the Department of Planning Monitoring and Evaluation in the Office of the President amongst her most interesting projects to date. She also contributed to the design of the strategic plan for the Primary Healthcare branch at the NDOH, as well as the Health and Social Development Services division of the Royal Bafokeng Nation.
She holds a medical degree (MBBCh) from Wits and an Masters in Business Administration (MBA) from UCT
Prof. Christopher-Paul Milne
Energizing the Industry Antibiotics Pipeline through Push-Pull Incentives
He is currently Director of Research at Tufts Center for the Study of Drug Development (CSDD) in Boston, USA, Research Associate Professor at Tufts University Medical School, Innogen Center Associate (University of Edinburgh), as well as a member of the editorial boards of the Drug Information Association’s journal (TIRS) and Pharma Focus Asia. Dr. Milne received a BA from Fordham University, an MPH from The Johns Hopkins University, and holds doctoral degrees in veterinary medicine and law, respectively from the UNPHU and UNH School of Law. He has published over 70 book chapters, white papers, and journal articles. His work aims to address legal and regulatory issues that affect the R&D of new drugs and biologicals.
His current research interests include: challenges to the R&D of new drugs; academic-industry collaborations; disease, demographic and market access factors in the emerging markets; innovation capacity in the developing world; incentive programs for pediatric studies, orphan products, and neglected diseases; assessing the impact of regulatory policy; medical countermeasures (MCMs) for infectious diseases and antimicrobial resistance; and, tracking the progress of new regulatory and research initiatives such as regulatory science, translational medicine, personalized medicine, and FDA User Fee programs.
Prof. Steven Ebert
Overcoming Clinical and Economic Barriers to the Treatment of Antimicrobial Resistant Bacterial Infections
As the Clinical Manager in Infectious Diseases at Meriter Hospital and Clinical Professor of Pharmacy at the University of Wisconsin in Madison, Prof. Steven Ebert will set the stage for the discussion of the economic side of development of antimicrobial products. He will address the clinical standpoint and describe the challenges of costs and reimbursement in patient care, giving you both, insights in development of antimicrobials as a pharmaceut and usage and a hospital worker.
His practice and research interests are antimicrobial resistance, antimicrobial pharmacokinetics/ pharmacodynamics, and appropriate utilization of healthcare resources. Dr. Ebert has served as a member of the Board of Directors of the Pharmacy Society of Wisconsin (PSW), Chairman of PSW’s Hospital Pharmacy Advisory Board, Chairman of WARN (Wisconsin Antibiotic Resistance Network), and as President of the Society of Infectious Diseases Pharmacists. He is a Follow of the American College of Clinical Pharmacy and the Infectious Diseases Society of America and has served as a member of the FDA Antiinfective Drug Advisory Committee from 2001-4. Dr. Ebert has published over 50 original research articles, review articles, and book chapters on optimizing antimicrobial use and dosing regimens.
Prof. Petra Reinke
Growing challenges in intensive medicine: multiresistant pathogens and strategies for sepsis care
Prof. Petra Reinke is the medical Director of Nephrology and Transplantation and also head of the “Kidney Transplant Outpatient Clinic” at the Department of Nephrology Charité Berlin. She is also head of platform D “immune system”, the GMP-Facility and Steering Committee Member of the Berlin-Brandenburg Center for Regenerative Therapies (BCRT). During her work Prof. Reinke was involved in major achievements in the field of t-cell-targeting and detection. Based on her occupation she initiated the development of new transplant models and founded the SME “Tecll Europe” (TCE).
She further developed biomarker studies in kidney transplant patients and implemented a new diagnostic test for transplant complications and immune responses.
Prof. Reinke was one of the first researchers dealing with the concept and therapy of “immunoparalysis” in ICU and sepsis patients and selective immunoadsorption in severe sepsis. As a member of the Committee for Recommendations in Infectious Diseases of the ATC, a reviewer for Nature and Science magazine and a member of several Editorial Boards of Journals such as “Transplant Infectious Diseases” and “Advances in Precision Medicine” she published 240 original and 20 review articles. Her research interests include transplantation medicine (immunology of acute/chronic rejection, cardiovascular complications, infectious complications, long-term outcome of transplant patients and development of new diagnostic and therapeutic approaches), adoptive T cell therapy and development of new therapeutic approaches for critically ill patients (sepsis).
She is also a member of the scientific advisory board of Pluristem Therapeutics Inc. and promotes Woman in research as a Mentor of the TTS initiative “Woman in Transplantation” and the SelmaMeyer Mentoring-Program at Heinrich-Heine Universität Düsseldorf.
Dr. David Treacher
Dr. David Treacher is Consultant in Intensive Care & Respiratory Medicine in the Department of Critical Care at Guy's & St. Thomas Hospital London, where he has made major contributions in the fields of sepsis and bedside Diagnostic in the intensive care unit. His research deals with patient outcome prognosis through blood analyses, sepsis research, new therapy appraches in crititcal care, respiratory medicine and internal medicine, especially cardiovascular physiolgy and pathophysiology.
Moreover he was involved in the research of a Speedy Blood test through FACS analysis of white blood cells, identifying a systemic bacterial Infection in under 2h and defining the role of neutrophiles in the develoment of sepsis complications.
He is also the Associate Clinical Dean of St Thomas’ Cluster at King's College London were he represents high quality teaching.
Prof. Enrico Baraldi
AMR- new economic models
Enrico Baraldi is Professor of Industrial Engineering & Management at the Department of Engineering Sciences, Uppsala University, and a core member of the IMI-financed DRIVE-AB project (Driving Reinvestment in R&D and Responsible Antibiotic Use), where he focuses on the design and simulation of alternative economic models for stimulating antibiotics R&D. He has 15 years of experience as researcher and consultant in the area of business and product development in complex inter-organizational networks from several industries (ICT, biotech, medtech, furniture, automotive, etc.). Next to value and supply chain analysis he specializes also in the field of innovation management and strategy development.
Another major area of concern in his research is the diffusion and commercialization of science, with for instance an ongoing comparison of Uppsala University and Karolinska Institute’s innovation strategies. His research is published in, among others, California Management Review, Technovation, Industrial Marketing Management, Journal of Business Research, Science & Public Policy, and the American journal of law & medicine. Enrico Baraldi is also engaged as ongoing evaluator of EU’s Regional Development Fund projects in the area of med-tech private-public partnerships and university commercialization strategies.
Prof. Dr. Stefan Schwarz
Use of Antibiotics and the Development of Antimicrobial Resistance in the Veterinary Medicine and Animal Production
Prof. Schwarz works for the Friedrich-Löffler-Institute as head of the research group ’Molecular Microbiology & Antimicrobial Resistance’. He is a Specialist Veterinarian in Molecular Genetics and Gene Technology, Epidemiology and Microbiology.
One of his major research focus is the molecular development of antibiotic resistance in gram-positive and gram-negative bacteria as well as the monitoring of antimicrobial susceptibility.
He will teach us about the use of antibiotics in veterinary medicine and subsequently show us how this can be one of the first steps in the path of the development of antimicrobial resistance. His talk will include all the relevant details that link the problem of rising antimicrobial resistance to the relationship between humans and animals.